Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | BRD4 | O60885 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | MB | P02144 | 1/20 | 0.61 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.61 |
| ▸ | CA3 | P07451 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10944710 | 1.00 | SMN1; SMN2 (0.64) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL7941715 | 1.00 | SMN1; SMN2 (0.64) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL28208686 | 0.92 | RAB9A (0.71) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL14384399 | 0.92 | RAB9A (0.71) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL9342637 | 0.90 | MAPT (0.66) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL8237172 | 0.90 | MAPT (0.58) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL9000756 | 0.89 | MEN1 (0.59) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL22009555 | 0.89 | TSHR (0.60) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL9000760 | 0.89 | MEN1 (0.59) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL10944727 | 0.89 | NPC1 (0.62) | SMN1; SMN2HTTL3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2724156-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | The Jackson Laboratory (US) | 2014-04-30 | — | — | EP | claimed |
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-07-18 | — | — | US | claimed |
| WO-2013003112-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-01-03 | — | — | WO | claimed |
| US-20250177344-A1 | DISULFONATE STILBENES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | Université de Nantes (FR) | 2025-06-05 | — | — | US | disclosed |
| US-12233041-B2 | Disulfonate stilbenes for use in the treatment of proliferative diseases | Université de Nantes (FR) | 2025-02-25 | — | — | US | disclosed |
| US-20220016068-A1 | DISULFONATE STILBENES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | Université de Nantes (FR) | 2022-01-20 | — | — | US | disclosed |
| US-20220016068-A1 | DISULFONATE STILBENES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | Université de Nantes (FR) | 2022-01-20 | — | — | US | disclosed |
| EP-3883922-A1 | DISULFONATE STILBENES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | Université de Nantes (FR) | 2021-09-29 | — | — | EP | disclosed |
| US-10207988-B2 | Methods and compositions for treatment of cancer and autoimmune disease | THE JACKSON LABORATORY (US) | 2019-02-19 | — | — | US | disclosed |
| EP-2724156-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | JACKSON LAB (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2724156-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | The Jackson Laboratory (US) | 2014-04-30 | — | — | EP | disclosed |
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013003112-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-01-03 | — | — | WO | disclosed |
| WO-2001010810-A1 | A PROCESS FOR THE PREPARATION OF DIVINYL STILBENE COMPOUNDS | CIBA SPECIALTY CHEMICALS HOLDING, INC. (CH) | 2001-02-15 | — | — | WO | disclosed |
| EP-0573573-B1 | MESOGENIC GLYCIDYL AMINES | DOW CHEMICAL CO (US) | 1999-09-29 | — | — | EP | disclosed |
| US-5360884-A | Coatings, adhesives, moldings, laminates and encapsulation | THE DOW CHEMICAL COMPANY (US) | 1994-11-01 | — | — | US | disclosed |
| EP-0573573-A1 | MESOGENIC GLYCIDYL AMINES | THE DOW CHEMICAL COMPANY (US) | 1993-12-15 | — | — | EP | disclosed |
| US-5262509-A | Curable coatings | THE DOW CHEMICAL COMPANY (US) | 1993-11-16 | — | — | US | disclosed |
| WO-1992015630-A2 | MESOGENIC GLYCIDYL AMINES | THE DOW CHEMICAL COMPANY (US) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177344-A1 | DISULFONATE STILBENES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | RB1, ARSA, SDHB | SMN1; SMN2 1934/4885HTT 522/4885L3MBTL1 2662/4885 |
| US-20220016068-A1 | DISULFONATE STILBENES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | RB1, ARSA, SDHB | SMN1; SMN2 1934/4885HTT 522/4885L3MBTL1 2662/4885 |
| US-12233041-B2 | Disulfonate stilbenes for use in the treatment of proliferative diseases | RB1, ARSA, SDHB | SMN1; SMN2 1934/4885HTT 522/4885L3MBTL1 2662/4885 |
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | BAK1, SSB, MRE11 | SMN1; SMN2 2316/4885HTT 3488/4885L3MBTL1 806/4885 |
| US-10207988-B2 | Methods and compositions for treatment of cancer and autoimmune disease | BAK1, SSB, MRE11 | SMN1; SMN2 2316/4885HTT 3488/4885L3MBTL1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.